Around 10 million people globally live with the life-threatening human T-cell lymphotropic virus type-1 (HTLV-1), yet it ...

The approval to reduce proteinuria for those 12 and older with either of the two severe and rare kidney diseases came on the July 28 PDUFA date, a little more than four years after the company won ...

Med-tech companies raised $8.13 billion in the second quarter of 2025, a modest dip from the $8.32 billion recorded in Q1. While the quarterly total marks a continued improvement over 2023’s lower ...

Osteoporosis involves degradation of bone throughout the body, and it already affects nearly a quarter of a billion people in ...

Total venture capital funding in U.K. biotech was £1.23 billion (US$1.64 billion) in the first half of 2025, almost matching ...

Centauri Therapeutics Ltd. and Kinvard Bio Inc. have separately announced new funding from CARB-X (Combating ...

Collaborators in Australia, South Africa, Sweden and the U.K. have linked reduced levels of neuronal cell adhesion molecule ...

People with the subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) associated with fusion of MEF2D with other genes show quite poor prognosis. Most patients fail to respond to ...

PTC Therapeutics Inc. will be launching its oral phenylketonuria therapy, Sephience (sepiapterin) in both the U.S. and Europe this summer, following the U.S. FDA approval just ahead of its July 29 ...

Understanding neurological disease requires several things, including a clear view of the connectome, and the U.S. National Institutes of Health may have a solution in the form of a new MRI system ...

Chitinase-3-like protein 1 (CHI3L1) is a secretory glycoprotein from the glycoside involved in the regulation of immune and inflammatory responses. In the brain, CHI3L1 is primarily produced by ...

Intracerebral hemorrhage accounts for 10%-15% of all cases of stroke, and it is associated with particularly poor prognosis due to primary and secondary brain injury driven by neuroinflammation. This ...